Skip to main content

The viral and non-viral vector manufacturing market is projected to grow at an annualized rate of over 15%, claims Roots Analysis

 The rapidly growing pipeline of genetically modified therapies reflects the surge in demand for high quality vectors, presenting lucrative opportunities for companies with the capabilities to manufacture viral and non-viral gene delivery solutions

 

London

 

Roots Analysis has announced the addition of “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition) 2021 – 2030” report to its list of offerings.

 

Over time, ~15 cell and gene therapies have been approved across the world. Since transgene delivery into biological producing cell lines, gene modified cell-based therapies and the body, is an indispensable aspect of modern drug / therapy development efforts, high quality vectors are required by both medical researchers, drug developers and manufact7uring service providers, alike. In order to save time and costs, many stakeholders in the cell and gene therapy market have opted to outsource their vector manufacturing needs.

 

To order this 685+ page report, which features 170+ figures and 290+ tables, please visit https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html

 

Key Market Insights

 

The market features the presence of over 225 industry players and non-industry players

It is currently dominated by the presence of mid-sized players (51-500 employees), which represent more than 55% of industry stakeholders, worldwide. Of these, ~80% are capable of synthesizing different types of viral vectors, and round 10% of the companies mentioned in the report claim to have expertise in manufacturing plasmid DNA.

 

Over the time, several new technology platforms have been developed to deal with existing production-related challenges

Majority (85%) of the available technologies are currently focused on viral vectors. The technology  landscape analysis featured in the report, highlights the fact that 55% of the contemporary platforms are meant for the development and production of gene therapies.

 

Close to 210 partnerships were inked in this market, over the last five years

More than 55% of partnerships were inked post 2017, with the maximum activity being reported in 2020 (till September). Most of the deals (~27%) were manufacturing agreements, followed by product / technology licensing (24%), product development (17%) and R&D (9%) agreements.

 

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/274/request-sample.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis
Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more